Other Barks & Bites for Friday, May 15: PTAB Decisions on Inconsistent Claim Arguments Marked Informative; Bill Moving Copyright Office to Executive Branch Moves to House Floor; CJEU Upholds Right of Fair Compensation for Publishers

This week in Other Barks & Bites: the Legislative Branch Agencies Clarification Act moves one step closer toward enactment; the Federal Circuit reverses attorney’s fees award and attorney sanctions in a patent case over e-banking technology; the Court of Justice for the European Union finds that a publisher’s right to fair compensation established by EU member states is permissible if qualifying as consideration for the right to republish; Nokia earns a stay of UK court rulings in its RAND licensing battle over video codec patents with Acer and Asus; the U.S. Patent and Trademark Office places informative designations on a trio of Patent Trial and Appeal Board decisions applying agency precedent on inconsistent claim construction positions; Cisco announces 4,000 layoffs on the same day that it reported a 12% year-over-year jump in quarterly revenues; top Congressional Democrats publicly opposed President Trump’s ouster of the National Science Board membership; and the European General Court tells the European Union Intellectual Property Office that it did not sufficiently analyze links between an ammunition trademark and a famous French comic serial.

Patent Law Firms Face the AI Squeeze as Clients Internalize More Work

As in-house patent teams rethink how work is allocated, the implications for outside counsel are unavoidable. Corporate clients are asking whether work being done by outside counsel is being performed as efficiently as possible and even starting to ask whether it needs to be performed by outside counsel at all. At least some in-house teams are wondering whether the same or better result can be achieved internally using AI-enabled tools. If the answer is yes, then clients can be expected to decrease reliance on outside counsel, looking to law firm attorneys for targeted support, not end-to-end project management.

Beware the Siren’s Call of Industrial Policy

To say we live in perplexing times is an understatement. Everything seems to be shifting beneath our feet, often with seemingly little thought. One example is the move to change how the federal government supports research. It wasn’t until the passage of the Bayh-Dole Act in 1980, which injected the incentives of patent ownership into the system, that the situation changed. And the result was dramatic.

Evaluating the Business Case for AI in Patent Practice

Artificial intelligence has moved beyond the experimental phase in legal practice. The legal industry is no longer debating whether lawyers can or should use AI tools, or whether AI will affect the economics of law firm and in-house legal department operations. Those questions have been answered. AI is already reshaping how legal work is performed, how legal departments manage demand, how law firms are expected to price services, how patent teams analyze portfolios, and how clients evaluate outside counsel.

The Real Cost of Weakening Drug Patents

When the Food and Drug Administration (FDA) approved a new, easier-to-administer version of a popular cancer medicine called Keytruda a few months ago, patients celebrated. But critics quickly cried foul, accusing the drug’s manufacturer of gaming the patent system to preserve its monopoly and prevent cheaper competitors from coming to market. 

Gerasimow Law is Seeking an Associate Attorney

Gerasimow Law is seeking an Associate Attorney to provide core support to a Partner and Senior Associate across a diverse intellectual property docket. This role offers direct involvement in the technical and legal life cycle of a case, from initial filing through post-grant challenges. This position is fully remote with no in-office requirement. Candidates located in Illinois or Texas are a plus.

CAFC Says Generic Hypertension Drug Does Not Infringe Actelion’s Patents

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today affirming a district court ruling that Mylan Pharmaceuticals’ generic hypertension drug did not literally infringe Actelion Pharmaceuticals’ U.S. patents for its own hypertension drug, Veletri®. The CAFC also affirmed the district court’s holding that Actelion had not proven and was barred from asserting infringement by an equivalent.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates